Coronavirus: new hopes with the Moderna vaccine, improvement in France


The announcement of the effectiveness of the vaccine developed by the American biotechnology company Moderna, estimated at 94.5%, has sparked a wave of hope: the world is preparing for vaccination. New restrictions are adopted in Europe to deal with the second wave; in France, the curves are giving encouraging signs.

  • The epidemic seems to be on the decline in France

The epidemic seems to be on the decline in France, where the curves of new hospital admissions are stabilizing. “If there are signs of improvement in terms of the epidemic, we have not yet conquered the virus”, warned the Minister of Health Olivier Véran on Monday, November 16, urging his fellow citizens to “Do not relax (their) efforts”. The daily report from Public Health France identifies 9,406 new positive cases for the coronavirus. The number of additional deaths in 24 hours, however, amounts to 508 people on Monday.

  • New hope with the Moderna vaccine

After Pfizer / BioNTech last week, the US biotech company Moderna announced Monday that its vaccine was 94.5% effective. This means that the risk of getting sick from Covid-19 was reduced by 94.5% between the placebo group and the vaccinated group of the large clinical trial underway in the United States. In this case, 90 participants in the placebo group caught Covid-19, compared to 5 in the vaccinated group.

TO SEE ALSO – The Moderna laboratory offers a vaccine against Covid-19 effective at 94.5%

  • US hopes to vaccinate 20 million people in December

The Pfizer / BioNtech and Moderna vaccines could be authorized by the United States Medicines Agency (FDA) in the first half of December, said Monday Moncef Slaoui, scientific head of Operation Warp Speed ​​responsible for vaccinating the American population. This would make it possible to vaccinate 20 million Americans, in priority probably the oldest and at risk, from the second half of December. In total, the United States estimates that with several vaccines, there will be enough doses by the beginning of April for the entire population.

As for Europe, officials have said it is possible to start vaccinations in January, subject to approval.

  • Free vaccine in Belgium

The Belgian government announced on Monday its intention to treat at least 70% of the country’s population, or 8 million people, with future vaccines against Covid-19, and to ensure that they are free “For every citizen”.

  • Tightening of restrictions in Northern Europe

Scandinavian countries, so far adherents of a more flexible health protocol than that of their European neighbors, took new measures on Monday to deal with the second wave of coronavirus. Sweden announced Monday to limit public gatherings to a maximum of eight people, a first. In Norway, the municipality of Oslo has announced the tightening of the rules of “social confinement” for adolescents, particularly affected by a recent rebound in the epidemic.

TO SEE ALSO – Covid-19: Sweden bans gatherings of more than 8 people

  • Austria submerged by the second wave

Austria begins a second lockdown on Tuesday, with the closure of schools and non-essential stores and a call to stay at home. The average number of daily contaminations was on Monday at 809 per million inhabitants over the last seven days, much more than in the United States (460) or in neighboring Germany (221).

  • More than 1.3 million deaths worldwide

The Covid-19 pandemic has killed at least 1,319,561 people worldwide since December. The United States is the most bereaved country with 247,116 deaths, ahead of Brazil (166,014), India (130,070), Mexico (98,542) and the United Kingdom (51,934).

  • The sale of Christmas trees soon authorized

Christmas may be confined, but will have its tree. A decree to authorize the sale of these Christmas trees will be published “in the next few days”, said the Minister of Agriculture, Julien Denormandie yesterday.

TO SEE ALSO – Covid-19: “The vaccine will not end the pandemic”, warns WHO

.

Leave a Reply

Your email address will not be published. Required fields are marked *